- In April 2024, Mute Snoring, a brand under Rhinomed Ltd., launched an upgraded version of its nasal dilator featuring enhanced airflow technology and a redesigned fit for improved comfort and user compliance. The updated device aims to address snoring and mild sleep apnea more effectively. This launch underscores the company’s ongoing commitment to innovation in the non-invasive respiratory solutions segment, aiming to expand its global market reach through pharmacy and e-commerce channels
- In March 2024, GlaxoSmithKline (GSK) expanded its over-the-counter (OTC) nasal health portfolio by partnering with a European medical device firm to co-distribute a clinically tested nasal dilator in the U.K. and Germany. The strategic collaboration is intended to address rising cases of sleep-related breathing disorders and to cater to growing consumer demand for drug-free nasal congestion solutions. This move aligns with GSK’s goal to strengthen its consumer healthcare business across Europe
- In February 2024, Sanolabor, a major healthcare product distributor in Central and Eastern Europe, entered into a distribution agreement with a U.S.-based nasal dilator manufacturer to supply advanced nasal breathing aids across Slovenia, Croatia, and Hungary. The partnership reflects a growing regional interest in non-pharmacological respiratory aids, especially amid increased awareness of sleep hygiene and breathing health
- In January 2024, Breathe Right, a brand owned by Haleon, introduced a limited-edition series of nasal strips targeting athletes and fitness enthusiasts in North America. These nasal dilators are designed to enhance airflow during physical activity, improving oxygen intake and performance. The launch taps into the growing intersection of sports wellness and respiratory health, aiming to capture a niche but rapidly expanding market segment
- In December 2023, Health Enterprises, a Prestige Consumer Healthcare company, announced the expansion of its nasal dilator product line into the Asia-Pacific region, beginning with India and Southeast Asia. The move is part of the company’s broader strategy to capture emerging market opportunities through affordable, OTC respiratory solutions tailored to regional needs, particularly in urban centers with high pollution levels and growing cases of sleep disturbances
